← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › VACCINES › BACTERIAL VACCINES › Meningococcal vaccines
meningococcus A,B,C,Y,W-135, pentavalent purified polysaccharides antigen conjugated and factor H binding protein
J07AH11
Forms & Strengths
- 0.5ml single dose vial
- meningococcus A 4mcg, B 10mcg, C 4mcg, W-135 4mcg, Y 4mcg per 0.5ml
Adult Dosing
- 0.5ml intramuscular injection
- booster dose may be needed 2-5 years after primary dose
Pediatric Dosing
- 2 months to 55 years: 0.5ml intramuscular injection
- primary series: 2 doses, 2 months apart for infants under 7 months, or single dose for 7 months and older
Indications
- prevention of invasive meningococcal disease
- high risk groups such as laboratory workers, military recruits, travelers
Mechanism of Action
- induces antibodies against meningococcal A, B, C, W-135, and Y capsular polysaccharides and factor H binding protein
- protects against invasive disease caused by serogroups A, B, C, W-135, and Y
Contraindications
- severe allergic reaction to previous dose
- hypersensitivity to any component of vaccine
Adverse Reactions
- redness, pain, swelling at injection site
- fatigue, headache, muscle or joint pain
Drug Interactions
- co-administration with other vaccines may increase risk of adverse reactions
- use caution with immunosuppressive therapy
Curated Content: Needs Vetting Before Put to Clinical Use